Emerging Cancer Diagnostic Markets: Innovative Technologies and Strategic Profiles of Leading Suppliers
This report provides detailed assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.
CURRENT AND EMERGING TECHNOLOGIES
MONOCLONAL AND POLYCLONAL ANTIBODIES
IMMUNOASSAYS
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
MOLECULAR DIAGNOSTICS
a. Technology Overview
b. Amplification Methods
PCR
DAP-PCR
Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
CHROMOSOME ANALYSIS
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
ARTIFICIAL INTELLIGENCE
Flow Cytometry
Two Dimensional Gel Electrophoresis (2-DGE)
Biosensors
COMPETING/COMPLEMENTING TECHNOLOGIES
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
COMPETITIVE PROFILES
The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic
Leica Biosystems
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako and others.
MONOCLONAL AND POLYCLONAL ANTIBODIES
IMMUNOASSAYS
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
MOLECULAR DIAGNOSTICS
a. Technology Overview
b. Amplification Methods
PCR
DAP-PCR
Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
CHROMOSOME ANALYSIS
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
ARTIFICIAL INTELLIGENCE
Flow Cytometry
Two Dimensional Gel Electrophoresis (2-DGE)
Biosensors
COMPETING/COMPLEMENTING TECHNOLOGIES
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
COMPETITIVE PROFILES
The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic
Leica Biosystems
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako and others.